Is RADX or RCUS more undervalued in 2026?

CirclFi compares Radiopharm Theranostics Limited (RADX) and Arcus Biosciences, Inc. (RCUS) using 13 institutional-grade valuation models. RADX has a Quality of Company score of 1.7/10 while RCUS scores 6.4/10.

Which is a better buy — RADX or RCUS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RADX and RCUS valuations compare?

RADX at $4.62 and RCUS at $24.48 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RADX vs RCUS Valuation Comparison 2026 — Intrinsic Value Analysis

RADX

Biotechnology

Radiopharm Theranostics Limited

Quality

1.7

out of 10

Value Trap

—

Price

$4.62

Last close

Models

10/13

Active

RCUS

Biotechnology

Arcus Biosciences, Inc.

Quality

6.4

out of 10

Value Trap

LOW

Price

$24.48

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	RADX Fair Value	RADX Upside	RCUS Fair Value	RCUS Upside
Bayesian DCF	Intrinsic	$1.22	-73.5%	$5.49	-77.6%
Earnings Power Value	Intrinsic	$2.66	-40.3%	$12.78	-49.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RADX vs RCUS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RADX vs RCUS — Which Stock Is More Undervalued?

RCUS scores higher with a 6.4/10 quality rating vs RADX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Radiopharm Theranostics Limited (RADX) and Arcus Biosciences, Inc. (RCUS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RADX currently trades at $4.62 with a QOC of 1.7/10, while RCUS trades at $24.48 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).